KOD - Kodiak Sciences Inc.
About Kodiak Sciences Inc. (https://kodiak.com)
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Victor Perlroth | Co-Founder, Chairman, Chief Executive Officer & President | 1974 | $1,576,189 USD |
| John A. Borgeson | Executive Vice President, Chief Financial Officer & Secretary | 1963 | $937,157 USD |
| Hong Liang | Senior Vice President of Development | 1972 | $300,709 USD |
| Almas Qudrat | Chief Quality Officer | – | – |
| Dolly S. Chang | Chief Scientific Officer | – | – |
| J. Pablo Velazquez-Martin | Chief Medical Officer | – | – |
| Laurent Ducay | Senior Vice President of Biologics Development & Manufacturing | – | – |
| Laurent Ducry | Senior Vice President of Biologics Development & Manufacturing | – | – |
| Stephen Raillard | Senior Vice President of Chemical Development & Manufacturing | – | – |
| Wayne To | Chief Technology Officer | – | – |